John J.V. McMurray works in Heart Failure / Cardiomyopathy affiliated with University of Glasgow.
John J.V. McMurray is Professor of Medical Cardiology at the University of Glasgow and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. He served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at Brigham and Women’s Hospital and visiting Professor of Medicine at Harvard University in 2010/2011. He is a past president of the Heart Failure Association of the ESC and has led or co-led major trials including DAPA-HF, PARADIGM-HF and DELIVER.
2,577 pubs · 315,811 cites · h-index 223
BSc (Hons)
University of Manchester
1980
MB ChB (Hons)
University of Manchester
1983
MD
University of Dundee
1990
Professor of Medical Cardiology and Honorary Consultant Cardiologist
University of Glasgow / Queen Elizabeth University Hospital · 1995 - Present
Professorial Fellow
Australian Catholic University (Mary MacKillop Institute for Health Research) · 2017 - Present
Eugene Braunwald Scholar in Cardiovascular Disease and Visiting Professor of Medicine
Brigham and Women's Hospital / Harvard University · 2010 - 2011
Consultant Cardiologist
Edinburgh · 1993 - 1995
Protocol-guided finerenone titration may limit hyperkalemia in HF; leaves open translation to cardiovascular outcomes.
Expert commentary · @franciscojlk
Sometimes the evidence-practice gap is not about efficacy. It is about implementation. 📬 A very interesting pragmatic trial presented today at #ESCCongress 2026: EMAIL-HF, evaluating whether a simple digital strategy could increase implementation of SGLT2 inhibitors in
JACC Heart FailureMalik et al.
NT-proBNP interpretation in HFrEF may differ by AF status; leaves open need for AF-specific thresholds before practice change.
Finerenone benefits apply across CKM multimorbidity levels in HFmrEF/HFpEF; extends RCT applicability to high-risk multimorbid patients.
Congestion signs refine risk stratification in HFpEF and HFrEF; extends pooled RCT evidence by quantifying burden-specific hazards across phenotypes.
Supports SBP control to 110-<130 mmHg in HFmrEF/HFpEF; confirms and extends guideline recommendations in large pooled RCT data.
Empagliflozin can be added to ARNI or MRA in HFrEF with diabetes; extends remodeling benefit to contemporary background therapy.
Sacubitril/valsartan lowers NT-proBNP more than enalapril in Chagas HFrEF; extends ARNI benefits to this etiology.
Baseline natriuretic peptide levels stratify early risk after acute HF hospitalization; confirms prognostic value while extending consistent dapagliflozin benefit across levels.
B-lines on pocket LUS detect subclinical congestion missed by exam in ambulatory HFpEF; leaves open whether routine use improves outcomes.
Supports early valsartan in sarcomeric HCM; extends VANISH to CMR tissue remodeling.
Observational study reveals rising mortality from atrial fibrillation and valvular heart disease in US adults, indicating growing cardiovascular disease burdens.
Cardiologist, Brigham and Women's Hospital, Harvard
Across a broad range of ages, these therapies, when implemented in combination, may meaningfully improve life expectancy and help patients remain out of the hospital.
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Vaduganathan et al.
Cardiologist and senior research fellow, The George Institute for Global Health · The George Institute for Global Health
By providing a personalised estimate of what to expect when initiating combination therapy, the calculator can reduce uncertainty and give clinicians greater confidence to prescribe these treatments simultaneously, ultimately helping more patients receive therapies that improve long-term outcomes.
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Wang et al.
May aid post-MI ICD risk stratification; extends GRACE/VALIANT-HF models but leaves open prospective validation.
Febuxostat does not increase the risk of cardiovascular events or mortality compared to allopurinol, challenging previous concerns raised by the CARES trial.
